[ad_1]
Merck Animal Health, a medical company focused on veterinary medicine, has signed an agreement to acquire the aquatic-focused business of Elanco Animal Health for $1.3 billion (€1.2 billion) in cash.
Merck Animal Health said the deal includes Elanco’s entire portfolio of pharmaceuticals, vaccines, nutrients and aquatic supplements, two associated manufacturing facilities in Vietnam and Canada, and an associated research facility in Chile. Stated. The acquisition is expected to close by mid-2024, subject to regulatory approval, Merck said.
“We are excited to acquire Elanco’s Aqua products, solutions and the capabilities and expertise that the team brings to our business,” Merck Animal Health President Rick DeLuca said in a release. “We believe this acquisition, combined with our commercial and scientific capabilities, will deliver even greater benefits to our Aqua customers.”
The acquisition includes a portfolio of products including CLYNAV. – DNA-based vaccine for Atlantic salmon farming operations to prevent pancreatic disease – and IMVIXA – Anti-parasitic lice treatment. Other processing products for “hot water production” are also included, Merck said.
“After a robust process over the last year, Merck Animal Health has emerged as the right strategic buyer for our aquaculture business,” said Jeff Simmons, president and CEO of Elanco Animal Health. “I am confident that they will continue to deliver value to Aqua customers who rely on these products and create opportunities for our team to continue to grow.”
Merck also said the acquisition continues its focus on aquaculture-based medicines. In March 2019, the company acquired Scan Aqua, a Norwegian-based fish health and welfare company. A month later, in April 2019, the company acquired Antelliq Corporation, which develops tagging and tracking technology to monitor fish and wildlife. Then, in December 2019, it acquired Vaki, a company that developed aquaculture and wild fish conservation monitoring equipment and real-time video monitoring technology to estimate fish numbers and sizes.
Goldman Sachs served as financial advisor to Merck Animal Health and Covington & Burling served as legal advisor on the transaction.
“The addition of our innovative portfolio of cold and hot water aqua products spanning vaccines, anti-parasitic treatments, hydration and nutrients positions Merck Animal Health as a leader in the aqua space,” said DeLuca. he said.
Photo courtesy of Tada Images/Shutterstock
[ad_2]
Source link
